ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharmaceuticals is well positioned by a diversified base of Rare Disease, Brands, and Generics revenue, with 2Q 2026 sales of $266.0M and non-GAAP EPS of $2.21 both beating expectations. Although Cortrophin sales of $117.1M led to a FY 2026 guide cut to $520M-$540M, management’s 50% sales-force expansion, new acute gouty arthritis flares indication, and expected 2H26 ramp suggest stronger execution ahead and meaningful 2027 carryover. Supportive factors also include all-time-high Cortrophin prescriptions, 33.5% ACTH gel share, stronger-than-expected Generics sales, and higher brand royalty income, reinforcing confidence in longer-term growth and valuation.

ANI Pharmaceuticals is facing a cautious outlook because its key growth drivers carry meaningful execution and regulatory risk, especially for Purified Cortrophin Gel, Iluvien, and Yutiq, where any clinical, manufacturing, or commercial setback could disrupt momentum. The company also faces integration uncertainty tied to Alimera, alongside the possibility that it may struggle to complete attractive future deals, which could weaken its acquisition-led growth strategy. On top of that, generics look set to soften, as 1Q 2026 generics revenue of $105.4M was supported by a partnered launch that management expects to normalize in FY 2026, while 2Q 2026 prescription volumes fell 3.8% sequentially amid worsening pricing and competition.